Change in fat‐free mass (kg) · adults with disease‐related malnutrition
1 finding from 1 review
QoL · adults with disease‐related malnutrition
1 finding from 1 review
Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at 6 months: main analysis · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality at 6 months: main analysis compared with no prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes pulmonary embolism compared with no prophylaxis (very low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes symptomatic deep vein thrombosis compared with no prophylaxis (very low certainty).
1 finding from 1 review
Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher major bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher minor bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Quality of life ‐ not reported · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adequate pain relief as reported by women · women with perineal pain in the early postpartum period
NSAID may leads to higher adequate pain relief(4 hours after administration) compared with placebo (low certainty).
2 findings from 1 review
Need for additional analgesia (4 hours after administration) · women with perineal pain in the early postpartum period
It is very uncertain whether NSAID (single administration, any dose) changes need for additional analgesia (4 hours after administration) compared with paracetamol (very low certainty).
1 finding from 1 review
Need for additional analgesia (6 hours after administration) · women with perineal pain in the early postpartum period
NSAID (single administration, any dose) may leads to lower need for additional analgesia (6 hours after administration) compared with paracetamol (low certainty).
1 finding from 1 review
Maternal drug adverse effects number of women experiencing adverse effects · women with perineal pain in the early postpartum period
1 finding from 1 review
Maternal drug adverse effects (6 hours after administration) · women with perineal pain in the early postpartum period
It is very uncertain whether NSAID (single administration, any dose) changes maternal drug adverse effects (6 hours after administration) compared with paracetamol (very low certainty).
1 finding from 1 review
Neonatal drug adverse effects ‐ not reported · women with perineal pain in the early postpartum period
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for additional analgesia (4 hours after administration) · women with perineal pain in the early postpartum period
NSAID probably leads to lower need for additional analgesia(4 hours after administration) compared with placebo (moderate certainty).
1 finding from 1 review
Need for additional analgesia (6 hours after administration) · women with perineal pain in the early postpartum period
It is very uncertain whether NSAID changes need for additional analgesia (6 hours after administration) compared with placebo (very low certainty).
1 finding from 1 review
Maternal drug adverse effects(4 hours after administration) · women with perineal pain in the early postpartum period
1 finding from 1 review
Maternal drug adverse effects (6 hours after administration) · women with perineal pain in the early postpartum period
NSAID showed no clear difference in maternal drug adverse effects(6 hours after administration) compared with placebo (low certainty).
1 finding from 1 review